{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:33:13Z","timestamp":1757453593571,"version":"3.28.0"},"reference-count":25,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Our goal is to create a population pharmacokinetic (PK) model and identify the best loading dose (LD) of intravenous valproic acid for hospitalized Thai patients. Data from patients who received intravenous valproic acid and underwent measurement of serum valproic acid concentrations during hospitalization were collected retrospectively. A nonlinear mixed\u2010effects modeling approach was conducted to estimate the PK parameters of valproic acid. Covariates affecting the PK parameters of valproic acid were examined and ranked based on their impact on the model's performance. Monte Carlo simulations of 1000 patients were conducted to estimate the optimal LD of valproic acid. A total of 120 hospitalized patients (51.7% male) with 167 valproic acid concentrations were included in the study. A linear one\u2010compartment model with constant residual error was the best base model. An age\u2010covariate model was the best predictor of valproic acid clearance (CL). The typical values of CL and volume of distribution for valproic acid were 0.77 L\/h and 14.56 L, respectively. The LD of 1000\u20101200 mg intravenous was identified as the pragmatic option as an empirical regimen for hospitalized Thai patients. The recommended time to initiate maintenance dose (MD) is 4\u20108 h following the LD. The population PK model and optimal LD of valproic acid in hospitalized Thai patients has been established, and it may be advisable to initiate the MD at a later time for the elderly.<\/jats:p>","DOI":"10.1002\/jcph.6102","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T16:29:27Z","timestamp":1722270567000},"page":"1343-1350","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics and Loading Dose Optimization of Intravenous Valproic Acid in Hospitalized Thai Patients"],"prefix":"10.1002","volume":"64","author":[{"given":"Sirima","family":"Sitaruno","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences Prince of Songkla University  Hat Yai Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tusavadee","family":"Chumin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences Prince of Songkla University  Hat Yai Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yada","family":"Ngamkitpamot","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences Prince of Songkla University  Hat Yai Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warunee","family":"Boonchu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmaceutical Sciences Prince of Songkla University  Hat Yai Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suwanna","family":"Setthawatcharawanich","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine of Internal Medicine Faculty of Medicine Prince of Songkla University  Hat Yai Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"volume-title":"Lexi\u2010drugs multinational","year":"2023","author":"Lexicomp Online","key":"e_1_2_10_2_1"},{"volume-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics","year":"2023","author":"Metcalf CS","key":"e_1_2_10_3_1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00440.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040811"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.09.017"},{"volume-title":"Lexi\u2010Tox Online","year":"2023","author":"Lexicomp Online","key":"e_1_2_10_7_1"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00409-5"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.04.005"},{"issue":"4","key":"e_1_2_10_10_1","first-page":"195","article-title":"Population pharmacokinetics of valproic acid in epileptic patients at Prasat Neurological Institute","volume":"32","author":"Senawin W","year":"2014","journal-title":"Songkla Med J"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01098.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.077180"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq815"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520952281"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03246-2"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0699-7"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0712-x"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2017.91"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1333"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1037239"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2016.1206164"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9695-z"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.6102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T14:50:47Z","timestamp":1729867847000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.6102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/jcph.6102"],"URL":"https:\/\/doi.org\/10.1002\/jcph.6102","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"2024-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}